Eli Lilly’s Path to $1 Trillion Runs Directly Through the AI Boom

1 hour ago 2

Rich Duprey

Mon, April 6, 2026 astatine 9:54 AM CDT 4 min read

Eli Lilly (LLY) generated $65.18B successful full-year 2025 revenue, up 44.7% year-over-year, driven by its GLP-1 franchises Mounjaro and Zepbound which bid 60% of the weight-loss market, with 2026 gross guidance of $80B to $83B and an expected Orforglipron FDA support successful Q2 2026 introducing the archetypal oral GLP-1 pill.
Wall Street’s $1,209.21 statement terms people and Lilly’s aggregate upcoming catalogs—including an AI cause find concern with NVIDIA, a $2.75B woody with Insilico Medicine, and Medicare enlargement capping out-of-pocket costs astatine $50 per month—position the institution to surpass a $1 trillion marketplace cap.
If you're focused connected picking the close stocks and ETFs you whitethorn beryllium missing the bigger picture: status income. That is precisely what The Definitive Guide to Retirement Income was created to solve, and it's escaped today. Read much here

Eli Lilly (NYSE:LLY) has built 1 of the astir singular maturation stories successful modern pharmaceutical past done its GLP-1 franchises. Mounjaro and Zepbound conquered the weight-loss market, giving Lilly astir a 60% stock of the weight-loss opportunity, a dominance that pushed full-year 2025 gross to $65.18 billion, up 44.7% year-over-year. Shares person pulled backmost 12.8% year-to-date from a beardown 2025 run. The question: tin Lilly scope $1,120, the terms that would propulsion its marketplace headdress past $1 trillion?

The statement one-year terms people sits astatine $1,209.21, implying important upside from the existent terms of $935.58. The expert breakdown: 24 Buy ratings, 6 Hold, and conscionable 1 Sell. Lilly's 2026 gross guidance of $80 cardinal to $83 cardinal and EPS guidance of $33.50 to $35.00 springiness analysts factual numbers to physique on. The institution bushed gross expectations successful each 4 quarters of 2025 and bushed EPS estimates successful 3 of 4 quarters, suggesting guidance is conservative.

Lilly presently trades astatine a guardant aggregate comparative to the midpoint of its 2026 EPS guidance. Hitting $1,120 would connote a meaningfully higher guardant aggregate connected 2026 earnings. For a institution guiding to non-GAAP EPS of $33.50 to $35.00 aft increasing nett income 94.9% successful 2025, that aggregate is tenable against the S&P 500's 21x to 23x guardant earnings.

If you're focused connected picking the close stocks and ETFs you whitethorn beryllium missing the bigger picture: retirement income. That is precisely what The Definitive Guide to Retirement Income was created to solve, and it's escaped today. Read much here

Several catalysts are already successful motion:

Read Entire Article